Cell Therapy Cuts Duchenne Muscle Decline by 54% in Phase III Trial
Deramiocel slowed upper limb decline by 54% and preserved heart function in boys with Duchenne muscular dystrophy in a landmark phase III trial.
Summary
A new cell therapy called deramiocel significantly slowed muscle and heart decline in boys and young men with Duchenne muscular dystrophy. In the phase III HOPE-3 trial, patients receiving quarterly infusions of deramiocel experienced 54% slower upper limb decline compared to placebo over 12 months. The therapy also slowed loss of independent feeding ability by 83% and preserved heart function, reducing cardiac fibrosis. Deramiocel works by delivering allogeneic cardiosphere-derived cells that reduce inflammation and fibrosis — two key drivers of disease progression. The trial met all primary and secondary endpoints, marking a meaningful advance for a condition with limited treatment options and life-threatening cardiac complications.
Detailed Summary
Duchenne muscular dystrophy is a devastating genetic disease that progressively destroys skeletal and heart muscle, primarily in males. Caused by mutations in the DMD gene that eliminate the protein dystrophin, the condition leads to wheelchair dependence, loss of arm function, and ultimately fatal cardiac events. A new cell therapy may meaningfully slow this trajectory.
In the phase III HOPE-3 trial presented at the American Academy of Neurology annual meeting, 106 patients aged 10 and older were randomized to quarterly infusions of deramiocel or placebo. After 12 months, those receiving deramiocel showed 54% slower decline in upper limb function as measured by the Performance of Upper Limb 2.0 scale. Mid-level arm function — closely tied to daily independence — declined 65% more slowly, and the ability to feed independently declined 83% more slowly.
Cardiac outcomes were equally compelling. Deramiocel preserved left ventricular ejection fraction with a 2.4% treatment difference and reduced late gadolinium enhancement, a marker of cardiac scarring, by 3.0 segments. Both findings were statistically significant. The therapy was reported as safe and well tolerated across the trial population.
Deramiocel consists of allogeneic cardiosphere-derived cells — cells originally derived from heart tissue — that exert immunomodulatory and anti-fibrotic effects. Rather than replacing lost muscle, the therapy appears to dampen the inflammatory and fibrotic processes that accelerate degeneration. This mechanism has broader implications for other fibrotic and inflammatory muscle diseases.
Important caveats apply. The trial enrolled a specific population — mostly non-ambulatory males averaging 15 years old — so generalizability to younger or ambulatory patients is unclear. The 12-month window limits conclusions about long-term durability. Deramiocel is currently under FDA review, and regulatory approval is not yet confirmed. Independent peer-reviewed publication of full trial data is still pending.
Key Findings
- Deramiocel slowed upper limb functional decline by 54% versus placebo over 12 months in Duchenne patients.
- Mid-level arm function tied to daily independence declined 65% more slowly with deramiocel treatment.
- Independent feeding ability was preserved 83% better in the deramiocel group versus placebo.
- Deramiocel preserved heart ejection fraction and reduced cardiac fibrosis markers significantly at 12 months.
- The therapy uses allogeneic cardiosphere-derived cells to reduce inflammation and fibrosis driving disease progression.
Methodology
This is a meeting coverage news report from MedPage Today summarizing phase III randomized controlled trial data presented at the AAN 2026 annual meeting. The HOPE-3 trial was double-blind and placebo-controlled with 106 participants, representing a high evidence standard. Full peer-reviewed publication has not yet been confirmed, so data should be treated as preliminary conference findings.
Study Limitations
The trial population was predominantly non-ambulatory older adolescents, limiting applicability to younger or ambulatory Duchenne patients. The 12-month follow-up does not establish long-term durability of benefit or safety. Full peer-reviewed publication is pending, and conference-reported data may differ from final published results.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.